Global Kinetics to present at philanthropic forum
Melbourne-based medical technology company Global Kinetics Corporation will present details of its Parkinson’s Kinetograph (PKG) at the Cavendish Global Health Impact Forum next month.
The company has been selected to present at the philanthropic forum, which will be held in New York from 5-7 May.
The company’s PKG technology is designed to record data about the presence and severity of Parkinson’s symptoms bradykinesia and dyskinesia, to allow neurologists to objectively analyse a patient’s movement disorder symptoms.
Movement data is collected via a wrist-worn device, which also has the capability to remind Parkinson’s patients to take their medication on schedule.
The PKG is approved in Australia and Europe, and is in use in nine countries worldwide.
Global Kinetics CEO Andrew Maxwell said presenting at the forum will give the company an “opportunity to interact with many of the world’s leading scientific minds, thought leaders and generous philanthropic individuals and families who are dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global is an alliance of over 150 family offices and philanthropic foundations with combined assets of over $190 billion.
Global Kinetics Corporation was founded in 2007 to commercialise technology developed by researchers from the Florey Institute of Neuroscience & Mental Health.
Targeting the stress system reduces Parkinson's tremors
The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...
DDX53 gene linked to autism spectrum disorder
While DDX53, located on the X chromosome, is known to play a role in brain development...
ADHD drug shows promise for treating meth addiction
A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be...
